RxDoctor Payments Data

Hiren Patel, MD

Cardiovascular Disease · Port Charlotte, FLNPI 1114951225

Payments from drug & device makers

$16,134in general payments, 2019–2025

Across 332 payments — averaging $48.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Abbott$2K
  • Penumbra, Inc.$936
  • Bayer$547
  • Boston Scientific$474
  • Merck$450
  • plus $5K from 35 others

What the payments were for

  • Grants$6,12538%
  • Travel & lodging$1,79611%
  • Food & beverage$8,06350%
  • Education$1501%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,134 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,564,971
Medicare patients
771
Services billed
9,772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban361$434,759
Repatha SureclickEvolocumab74$95,773
BrilintaTicagrelor88$88,445
EntrestoSacubitril/Valsartan63$87,690
MultaqDronedarone Hcl57$75,154
JardianceEmpagliflozin52$67,847
XareltoRivaroxaban41$48,968
Repatha SyringeEvolocumab34$34,578
FarxigaDapagliflozin Propanediol18$26,518
Praluent PenAlirocumab14$16,712
Metoprolol Succinate1,044$13,152
Ezetimibe475$11,260
VascepaIcosapent Ethyl16$9,609
ClopidogrelClopidogrel Bisulfate692$7,921
Rosuvastatin Calcium485$7,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$208$434,759361 claims
AstraZenecaBrilinta, Farxiga$399$114,963106 claims
NovartisEntresto$313$87,69063 claims
Sanofi-aventis U.S. LLCMultaq$318$75,15457 claims
Boehringer IngelheimJardiance$220$67,84752 claims
Johnson & JohnsonXarelto$125$48,96841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Port Charlotte

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →